Intuitive Surgical
ISRG
$421.12
-1.62%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, developing, producing, and marketing the da Vinci surgical system along with associated instruments, accessories, and services. The company is the dominant market leader in its field, having established a formidable competitive moat through its extensive installed base of over 10,000 systems worldwide and a deep ecosystem that locks in surgeons via training and recurring instrument purchases. The current investor narrative is a tale of two forces: robust underlying business performance, evidenced by a recent strong earnings beat and raised long-term growth forecast, is being weighed against significant regulatory and product safety concerns, specifically an FDA flag on a surgical stapler, which introduces near-term uncertainty and potential reputational risk.…
ISRG
Intuitive Surgical
$421.12
Related headlines
Investment Opinion: Should I buy ISRG Today?
Rating & Thesis: Hold. ISRG is a high-quality company trapped in a high-valuation, high-uncertainty moment, where near-term regulatory risks offset long-term fundamental strengths, suggesting investors should wait for clarity before committing new capital. This aligns with the mixed but cautious analyst sentiment, which includes recent upgrades (Citigroup) alongside neutral stances (UBS).
Supporting Evidence: The Hold rating is supported by four key data points: 1) The valuation remains elevated with a forward P/E of 38.8x, demanding perfect execution; 2) Underlying business performance is undeniably strong, with 18.8% YoY revenue growth and a 30.2% operating margin; 3) The stock exhibits severe technical weakness, underperforming the S&P 500 by 13.35% over three months; and 4) Analyst revenue estimates show a wide range ($18.5B-$20.0B), reflecting high uncertainty. The fortress balance sheet (D/E 0.017) and strong FCF ($2.49B TTM) provide a margin of safety but do not fully offset the valuation and regulatory concerns.
Risks & Conditions: The two biggest risks are a worsening of the FDA stapler situation and a growth deceleration that compresses the forward P/E multiple. This Hold would upgrade to a Buy if the stock declines further toward strong support at $428 (the 52-week low) without a deterioration in fundamentals, or if the FDA concern is resolved favorably, removing the overhang. It would downgrade to a Sell if QoQ revenue growth decelerates below 10% or if operating margins contract below 28%. The stock is currently fairly valued to slightly overvalued relative to its own growth trajectory and near-term risks, but deeply undervalued relative to its long-term competitive positioning.
Sign up to view all
ISRG 12-Month Price Forecast
The 12-month outlook for ISRG is a battle between stellar fundamentals and potent near-term headwinds. The base case (50% probability) of choppy, range-bound trading is most likely, as the FDA issue is unlikely to vanish quickly but the underlying business is too strong to collapse. The bull case requires a swift and clean regulatory resolution, while the bear case hinges on that issue worsening. The AI stance is Neutral with Medium confidence, as the path of the regulatory catalyst is unpredictable. This stance would upgrade to Bullish on confirmation the stapler issue is immaterial to financials, or downgrade to Bearish on any guidance cut linked to the FDA or competitive pressures.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $547.46 and implied upside of +30.0% versus the current price.
Average Target
$547.46
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$337 - $547
Analyst target range
Analyst coverage is robust with 15 firms providing estimates, and recent institutional ratings show a mix of actions including a notable upgrade to 'Buy' from Citigroup in March 2026, while others like UBS have maintained 'Neutral' stances. The consensus sentiment leans bullish, as evidenced by the upgrades and maintained 'Overweight' or 'Outperform' ratings from firms like Barclays, Piper Sandler, and Bernstein, though the absence of a consensus price target in the data prevents a precise upside calculation. The target price range, implied by revenue estimates, is wide, with a low estimate of $18.48 billion and a high of $20.00 billion for the coming year, reflecting significant uncertainty or divergent views on the company's growth trajectory and margin profile; the high target likely assumes successful navigation of regulatory issues and continued market share gains, while the low target may price in more severe competitive or operational headwinds.
Bulls vs Bears: ISRG Investment Factors
The evidence is currently balanced but tilts bearish in the near term due to the potent combination of a high valuation and a specific, unresolved regulatory overhang. The bull case is built on a fundamentally superb business with robust growth, exceptional profitability, and a dominant moat. The bear case centers on a valuation that remains demanding despite a significant price decline and a tangible regulatory risk that has triggered institutional selling. The single most important tension in the investment debate is whether the company's strong underlying operational performance (18.8% revenue growth, 30%+ operating margins) can quickly overcome and neutralize the FDA-related reputational risk before valuation multiples compress further. The resolution of the stapler issue and subsequent analyst commentary will be the key determinant of near-term price direction.
Bullish
- Robust Revenue Growth & Recurring Mix: Q4 2025 revenue grew 18.8% YoY to $2.87B, driven by the high-margin Instruments & Accessories segment ($1.66B). This shift towards recurring consumables, which now represents over 57% of revenue, provides predictable cash flow and deepens customer lock-in.
- Exceptional Profitability & Fortress Balance Sheet: The company maintains strong gross (66.4%) and operating (30.2%) margins, translating to a net margin of 28.4%. It has a debt-to-equity ratio of just 0.017, a current ratio of 4.87, and generated $2.49B in TTM free cash flow, providing immense financial flexibility.
- Dominant Market Position & Moat: With over 10,000 da Vinci systems installed globally, Intuitive has a formidable installed base and ecosystem that locks in surgeons via training. This creates a significant competitive moat and recurring revenue stream that is difficult for new entrants to disrupt.
- Strong Analyst Sentiment & Recent Upgrade: Analyst coverage is robust with 15 firms, and sentiment leans bullish, including a notable upgrade to 'Buy' from Citigroup in March 2026. This institutional support suggests confidence in the company's ability to navigate near-term headwinds.
Bearish
- Elevated Valuation Despite Recent Decline: Even after the sell-off, the forward P/E of 38.8x and trailing P/E of 70.8x are extremely high, demanding flawless execution. The PEG ratio of 3.17 suggests the stock is expensive relative to its growth rate, leaving little room for error.
- Regulatory & Product Safety Headwind: A recent FDA flag on a surgical stapler introduces significant near-term uncertainty and potential reputational risk. This specific regulatory overhang is a primary catalyst for the stock's recent underperformance and technical weakness.
- Severe Technical Weakness & Underperformance: The stock is in a pronounced downtrend, down 9.2% over 3 months while the S&P 500 gained 4.1%, resulting in severe relative weakness of -13.35. It trades near the lower end of its 52-week range ($427.84-$603.88), indicating persistent selling pressure.
- High Beta Amplifies Downside Volatility: With a beta of 1.679, ISRG is 68% more volatile than the market. This amplifies downside risk during market corrections and makes the stock unsuitable for risk-averse investors, as evidenced by its max drawdown of -24.09%.
ISRG Technical Analysis
The stock is in a pronounced downtrend, having declined 11.49% over the past year and currently trading at approximately 76% of its 52-week range, with a price of $457.78 relative to a 52-week high of $603.88 and low of $427.84. This positioning near the lower end of the range suggests the stock is in a state of technical weakness, though it may be approaching a potential support zone, presenting a dichotomy between a value opportunity and a 'falling knife' scenario. Recent momentum has been starkly negative and diverging from the broader market, with the stock down 1.44% over the past month and 9.21% over the past three months, while the S&P 500 (SPY) gained 9.98% and 4.14% over the same periods, respectively, resulting in severe relative weakness metrics of -11.42 and -13.35. This pronounced underperformance indicates significant stock-specific selling pressure, likely driven by recent negative catalysts rather than a broad market move. Key technical levels are clearly defined, with immediate support at the 52-week low of $427.84 and major resistance at the 52-week high of $603.88; a decisive break below support could signal a continuation of the downtrend, while a recovery above resistance would require a major positive catalyst. The stock's high beta of 1.679 confirms its status as 68% more volatile than the market, which amplifies both downside risk and potential upside, necessitating careful position sizing for risk management.
Beta
1.51
1.51x market volatility
Max Drawdown
-29.1%
Largest decline past year
52-Week Range
$418-$604
Price range past year
Annual Return
-24.8%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -10.1% | +5.6% |
| 3m | -13.3% | +8.4% |
| 6m | -23.4% | +10.0% |
| 1y | -24.8% | +25.2% |
| ytd | -25.1% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue reaching $2.87 billion, representing a strong 18.8% year-over-year increase, and the sequential quarterly trend from Q1 to Q4 2025 shows consistent top-line expansion from $2.25 billion to $2.87 billion. The growth is primarily driven by the high-margin, recurring 'Instruments and Accessories' segment, which generated $1.66 billion in the latest period, significantly outpacing the $786 million from 'Systems' and $422 million from 'Services'. This revenue mix shift towards consumables is a positive indicator for future margin stability and predictable cash flows. Profitability is exceptionally strong, with the company reporting net income of $794.8 million in Q4 2025 and maintaining a gross margin of 66.44%, which aligns with its trailing-twelve-month gross margin of 66.0%. Operating margins have shown stability, with the Q4 2025 operating margin at 30.2%, consistent with the full-year net margin of 28.4%, demonstrating the company's ability to convert high revenue growth into substantial bottom-line profits despite increased investment. The balance sheet is fortress-like, featuring a minimal debt-to-equity ratio of 0.017, a robust current ratio of 4.87, and strong cash generation with free cash flow (TTM) of $2.49 billion. The company's return on equity of 16.0% and return on assets of 10.2% reflect efficient use of its capital, and with $3.37 billion in cash from the latest quarterly statement, Intuitive has ample liquidity to fund growth initiatives, research and development, and share repurchases without relying on external financing.
Quarterly Revenue
$2.9B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given the company's substantial net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is elevated at 70.8x, while the forward P/E is 38.8x, based on estimated EPS of $16.83; this significant gap implies the market is pricing in expectations for substantial earnings growth over the next twelve months. Compared to sector averages, which are not provided in the data, a direct peer comparison cannot be quantified; however, a trailing P/E of 70.8x is typically indicative of a premium valuation that must be justified by superior growth rates and market leadership, which Intuitive Surgical possesses. Historically, the stock's own valuation has compressed from recent highs; the current trailing P/E of 70.8x is below the Q4 2025 historical ratio of 63.2x but remains elevated compared to its longer-term range, which has seen periods in the 50s and 60s. Trading near the upper end of its own historical band suggests the market still embeds high expectations for future execution, leaving little room for operational missteps or growth deceleration, especially in light of recent regulatory concerns.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~84x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Intuitive's primary financial risk is its absolute dependence on sustaining high growth to justify its premium valuation, with a forward P/E of 38.8x and a PEG ratio of 3.17. Any deceleration from the current 18.8% YoY revenue growth rate could trigger severe multiple compression. While the balance sheet is pristine (D/E 0.017), operational risk is concentrated in the recent FDA flag on a surgical stapler, which could lead to product recalls, usage restrictions, or litigation, directly impacting the high-margin Instruments segment that drives over half of revenue.
Market & Competitive Risks: The stock faces acute valuation compression risk, trading at a trailing P/E of 70.8x, which is historically elevated for the company itself. Its high beta of 1.679 makes it highly sensitive to broader market downturns and sector rotation out of growth stocks. While competitive disruption from new robotic surgery entrants is a perennial threat, the more immediate external risk is regulatory scrutiny expanding beyond the stapler issue, potentially slowing adoption rates or increasing compliance costs, as highlighted by the March 2026 news.
Worst-Case Scenario: The worst-case scenario involves the FDA stapler concern escalating into a mandatory recall or severe usage restrictions, coupled with a broader market downturn. This could trigger a simultaneous hit to revenue growth, margin compression from remediation costs, and de-rating of the valuation multiple. A realistic downside could see the stock re-testing and breaking below its 52-week low of $427.84, representing a potential loss of approximately -6.5% from the current price of $457.78. In a more severe scenario incorporating multiple compression, a drop toward the $400 level (-13% downside) is plausible if growth forecasts are materially cut.
FAQ
The key risks, ranked by near-term severity, are: 1) Regulatory & Product Risk: The FDA investigation into a surgical stapler could lead to recalls, restrictions, or reputational damage. 2) Valuation Risk: The high forward P/E (38.8x) and PEG ratio (3.17) make the stock vulnerable to multiple compression if growth slows even slightly. 3) Market Risk: With a beta of 1.68, ISRG is highly volatile and will likely fall more than the market in a downturn. 4) Execution Risk: The company must continue to innovate and defend its market share against well-funded competitors, all while integrating new platforms.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $480 and $520 as regulatory concerns linger but fundamentals hold. The Bull Case (30% probability) targets $580 to $604, requiring a clean FDA resolution and sustained growth. The Bear Case (20% probability) warns of a drop to the $428-$450 range if the FDA issue escalates. The most likely scenario is the Base Case, which assumes the stapler problem is a manageable headwind but not a franchise-threatening event. The wide analyst revenue target range ($18.5B-$20.0B) underscores this uncertainty.
ISRG is fairly valued to slightly overvalued based on near-term metrics, but potentially undervalued on a long-term, moat-adjusted basis. Its forward P/E of 38.8x and PEG ratio of 3.17 are premium, indicating the market prices in continued high growth. Compared to its own history, the trailing P/E of 70.8x remains elevated. The valuation implies the market expects flawless execution and a resolution to the FDA issue. Given the recent price decline, some near-term overvaluation has been corrected, but the stock is not deeply undervalued unless one has high conviction in decades of unassailable market dominance.
ISRG is a good stock to buy for long-term, growth-oriented investors who can tolerate volatility, but timing is crucial. At the current price of $457.78, the stock is down significantly from its highs and trades at a forward P/E of 38.8x, which is high but reflects its market leadership and 18.8% growth rate. The key impediment is the unresolved FDA safety flag on a surgical stapler, which creates near-term uncertainty. For a new investor, it may be prudent to initiate a small position or wait for clarity on the regulatory front. It is a less suitable buy for risk-averse or short-term investors.
ISRG is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. Its business model—locking in hospitals with systems and surgeons with training—creates value over many years, not quarters. The high beta (1.68) and lack of a dividend make it unsuitable for short-term trading or income seekers. Long-term investors can potentially ride out near-term volatility related to FDA news or market swings, allowing the company's competitive moat and recurring revenue streams to compound in value. Short-term traders face significant risk from unpredictable regulatory announcements and earnings volatility.